Investor mix
12 investors on record; lead investors include Kunming Pharmaceutical Group.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 33% |
| Private equity | 2 | 17% |
| Accelerator & incubator | 1 | 8% |
| Bank & private debt | 1 | 8% |
| Other / undisclosed | 4 | 33% |
Provides research and development for tumour immunotherapy
12 investors on record; lead investors include Kunming Pharmaceutical Group.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 33% |
| Private equity | 2 | 17% |
| Accelerator & incubator | 1 | 8% |
| Bank & private debt | 1 | 8% |
| Other / undisclosed | 4 | 33% |